[#item_full_content]BondBloxx aims to maximize after-tax returns with its new ETF, the IR+M Tax-Aware Short Duration ETF…
Category: Finance
Financial Health, Fintech, Investment, Payments
Fed Governor Bowman says additional rate hike could be needed if inflation stays high
[#item_full_content]Bowman said that it’s possible more hikes could be needed, rather than the cuts the market…
Fed Governor Bowman says additional rate hike could be needed if inflation stays high
[#item_full_content]Bowman said that it’s possible more hikes could be needed, rather than the cuts the market…
Here are some big money blind spots you need to avoid, advisors say
[#item_full_content]Here are some important aspects of personal finance you may be overlooking.
Free trade flaws fueled Trump’s rise in 2016 — and the problems remain, top economist says
[#item_full_content]Decades of trade deficits and a strong dollar created too many “losers” in the U.S. economy…
Free trade flaws fueled Trump’s rise in 2016 — and the problems remain, top economist says
[#item_full_content]Decades of trade deficits and a strong dollar created too many “losers” in the U.S. economy…
China’s Nio to expand battery swap services to gain an edge on EV infrastructure
[#item_full_content]Battery swapping takes only a few minutes and is expected to better address consumers’ driving range…
‘Biggest mistake’ bond investors may make ahead of Fed rate cuts
[#item_full_content]Experts advise taking advantage of opportunities in fixed income while yields are still high.
Here are some big money blind spots you need to avoid, advisors say
[#item_full_content]Here are some important aspects of personal finance you may be overlooking.
The Winners Circle Introduces Skill2Earn to Horse Racing
[#item_full_content]HONG KONG–(BUSINESS WIRE)– #Skill2Earn–The Winners Circle Introduces Skill2Earn to Horse Racing.
Here’s who Treasury Secretary Janet Yellen is going to meet in China
[#item_full_content]U.S. Treasury Secretary Janet Yellen was scheduled to arrive in China on Thursday ahead of four…
KKR says China’s real estate correction may only be halfway done
[#item_full_content]China’s real estate troubles are likely far from over and industry problems need to be addressed…
Fed’s Powell emphasizes need for more evidence that inflation is easing before cutting rates
[#item_full_content]Federal Reserve Chairman Jerome Powell said Wednesday it will take a while for policymakers to evaluate…
Fed’s Powell emphasizes need for more evidence that inflation is easing before cutting rates
[#item_full_content]Federal Reserve Chairman Jerome Powell said Wednesday it will take a while for policymakers to evaluate…
コンフォメーション・X・セラピューティクス、ステルス状態から脱却し、1350万ドル以上の資金調達で革新的な免疫腫瘍学パイプラインを推進
[#item_full_content]米マサチューセッツ州カントン–(BUSINESS WIRE)–（ビジネスワイヤ） — 免疫腫瘍分野に特化した医薬品開発企業であるコンフォメーション・X・セラピューティクスは、365万ドルの資金調達を完了し、創業以来の調達総額が1,350万ドルを超えたと発表しました。同社は、HHLA2およびIL18BPプログラムについて、ex vivoおよびin vivoでの概念実証試験に成功し、がん治療薬開発プロセスにおける重要なマイルストーンとなることを明らかにすることにより、同社の主要な資産を公開しました。 コンフォメーション・Xは、疾患生物学と薬効におけるタンパク質の立体構造の基本的な役割から発想を得て、新規免疫チェックポイント阻害剤の開発において比類ない精度を実現しています。同社は、既存の治療法では克服できなかったがんメカニズムに対処する、差別化された治療薬の包括的ポートフォリオを構築しています。 「現在のチェックポイント療法の限界は明らかで、非反応性や治療抵抗性に関連する多様なメカニズムを完全には標的にしていません」と、コンフォメーション・X・セラピューティクスのCEOであるアリ・H
Conformation-X Therapeutics sai do sigilo, garantindo mais de US$ 13,5 milhões em financiamento para impulsionar seu inovador pipeline de imuno-oncologia
[#item_full_content]CANTON, Massachusetts–(BUSINESS WIRE)–A Conformation-X Therapeutics, LLC, uma empresa de desenvolvimento de medicamentos com foco em imuno-oncologia,…
Conformation-X Therapeutics se dévoile et obtient un financement de plus de 13,5 millions de dollars pour promouvoir son pipeline innovant en immuno-oncologie
[#item_full_content]CANTON, Mass.–(BUSINESS WIRE)–Conformation-X Therapeutics, LLC, une société de développement de médicaments axés sur l’immuno-oncologie, a annoncé…
Conformation-X Therapeutics verlässt Stealth-Modus und sichert sich über 13,5 Mio. US-Dollar an Fördermitteln für die Entwicklung seiner innovativen Immunonkologie-Pipeline
[#item_full_content]CANTON, Massachusetts, USA–(BUSINESS WIRE)–Conformation-X Therapeutics, LLC, ein auf die Entwicklung von immunonkologischen Arzneimitteln spezialisiertes Unternehmen, hat…
Fed’s Powell emphasizes need for more evidence that inflation is easing before cutting rates
[#item_full_content]Federal Reserve Chairman Jerome Powell said Wednesday it will take a while for policymakers to evaluate…
Conformation-X Therapeutics走進公眾視野，獲得超過1350萬美元融資，將用於推動其創新型免疫腫瘤研發產品線的發展
[#item_full_content]麻薩諸塞州坎頓–(BUSINESS WIRE)–(美國商業資訊)– 專注於免疫腫瘤學的藥物開發公司Conformation-X Therapeutics, LLC今天宣布，其已完成一筆365萬美元的超額認購，使公司自成立以來的融資總額超過1350萬美元。該公司揭露了HHLA2和IL18BP計畫成功的體外和體內概念驗證研究，從而揭開了其主要資產的面紗，代表癌症藥物開發過程中的重要里程碑。 Conformation-X從蛋白質構象在疾病生物學和藥物療效中的基本作用汲取靈感，以無與倫比的精確性開發新型免疫檢查點抑制劑。公司正在打造一個全面的差異化療法組合，以解決現有療法無法解決的癌症機制問題。 Conformation-X Therapeutics執行長Ali H. Munawar博士表示：「目前檢查點療法的局限性顯而易見，因為它們不能完全針對與非回應性和耐藥性相關的各種機制。」 儘管PD-1/PD-L1抑制劑在癌症免疫療法中發揮著舉足輕重的作用，但若干同儕審查的臨床研究顯示，各種癌症的總體回應率仍保持在20%或以下。對傳統檢查點療法產生抗藥性的病患面臨著一系列挑戰。這包括腫瘤本身具有